TLC-2716 / OrsoBio - LARVOL DELTA

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: OrsoBio, Inc | Trial completion date: Feb 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Dyslipidemia • Hepatology • Hypertriglyceridemia • Metabolic Dysfunction-Associated Steatotic Liver Disease

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: OrsoBio, Inc

New P2 trial • Dyslipidemia • Hepatology • Hypertriglyceridemia • Metabolic Dysfunction-Associated Steatotic Liver Disease

A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants (clinicaltrials.gov) - P1 | N=100 | Completed | Sponsor: OrsoBio, Inc | Active, not recruiting ➔ Completed | N=150 ➔ 100

Enrollment change • Trial completion

Safety, Pharmacokinetics, and Lipid Lowering Effects of the Oral, Liver-Targeted Liver X Receptor (LXR) Inverse Agonist TLC-2716 in Healthy Volunteers (AHA 2023) - P1 | "The liver-targeted LXR inverse agonist TLC-2716 was well tolerated and caused significant lipid lowering in healthy subjects, supporting its evaluation in patients with SHTG and NASH."

Clinical • PK/PD data • Dyslipidemia • Hepatology • Hypertriglyceridemia • Non-alcoholic Steatohepatitis • ABCA1 • ABCG1

A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants (clinicaltrials.gov) - P1 | N=150 | Active, not recruiting | Sponsor: OrsoBio, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed